Niamh McGuinness is a technical lead with Privacy Analytics’ Clinical Trial Transparency (CTT) business unit, having joined the company in 2016. Her team specializes in statistical anonymization of clinical trial assets - both structured individual patient data and clinical trial documents. Drawing on her academic research background, Niamh has helped develop Privacy Analytics’ CTT methodology and proprietary toolsets, contributing to the ultimate goal of protecting patient privacy while also preserving the utility in clinical data.

Laura Dodd is the Director of Clinical Trial Transparency at Instem. Laura heads the DIA subgroup on EMA’s Policy 0043/FOIAs, which also covers redactions needed for Policy 0070 and Health Canada’s Public Release of Clinical Information. Laura started working in Data Sharing in 2014, which quickly required her to interact with many functional areas to obtain internal sponsor approval to share AND to fully protect both the intellectual property rights and protected personal data found in the documents. Prior positions include writing CSRs and submission summary documents for 20 years and coordinating research studies for industry, NIH, and the National Cancer Institute.

Jingyi is the one of the main drivers behind the data sharing and transparency initiatives at Lilly. He led the effort of data sharing through TransCelerate and worked closely with Vivli and ProjectDataSphere. In addition, he championed several projects to utilize the historical clinical trial data from TransCelerate to improve the efficiency of drug development. Jingyi has over 10 years of experience in the pharmaceutical industry across all stages of global clinical development of medical products, with extensive regulatory and submission related experience in different disease areas including oncology and autoimmune disease.